title: Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
abstract: OBJECTIVE
  We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks.
  
  
  METHODS
  Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed.
  
  
  RESULTS
  Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles.
  
  
  CONCLUSIONS
  All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.
authors.affiliation: Department of Medicine, Centre Leon Berard, 28 rue Laennec, 69008 Lyon, France. jean-yves.blay@lyon.unicancer.fr.
authors.forename: Jean Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Paolo
authors.initials: P
authors.lastname: Casali
authors.forename: Antonio
authors.initials: A
authors.lastname: Nieto
authors.forename: Adnan
authors.initials: A
authors.lastname: Tanović
authors.forename: Axel
authors.initials: A
authors.lastname: Le Cesne
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004149:Dioxoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008080:Liposarcoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077606:Trabectedin; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin